Calendario›AKTX›rVA576

rVA576

rVA576 in Adult Mild to Moderate Bullous Pemphigoid Subjects

Ensayo de Akari Therapeutics Plc en Penfigoide ampolloso (BP).

Fase

Fase 2

Estado

Completado

Participantes

9

previstos

Centros

2

Fin del objetivo primario

mar 2020

fecha real

Qué significa cada fase y cada estado.

Estudio de intervención, de un solo grupo, abierto. Comenzó en sep 2018.

Qué mide

Parametro de seguridad (42 dias)

Cómo lo describe el promotor

En el documentoEn inglés, del registroBullous pemphigoid (BP) is the most common of the autoimmune blistering skin diseases in Western Europe. \[Joly 2012\]The study will recruit the new onset or relapsing mild to moderate BP patients. The study population will consist of patients above the age of 18 years with an active episode of BP, confirmed by inclusion and exclusion criteria and who, in the opinion of the Investigator, would benefit from treatment with rVA576. Recombinant rVA576 is a small protein complement C5 and LTB4 inhibitor, which prevents the cleavage of C5 by C5 convertase and thereby inhibits generation of C5b-9 the membrane attack complex (MAC), as well as preventing the release of the anaphylatoxin C5a. rVA576 is effective in inhibiting terminal complement activity irrespective of the activating pathway (classical, lectin or alternative). This Phase IIa open-label single-arm study will evaluate the safety and efficacy of rVA576 in adult mild to moderate Bullous Pemphigoid patients

Más ensayos de AKTX

Todos los de AKTX, en su ficha.

Ficha completa en ClinicalTrials.gov (NCT04035733), actualizada en abr 2025.